The 30-second version. Pharma marketing isn’t content — it’s promotional material governed by review. Every outward-facing, claim-bearing piece clears MLR review (medical, legal, regulatory) before use, and from that moment four things decide whether the library is an asset or a liability: the piece must trace to the approved version, carry an expiry (approvals lapse; a piece withdrawn from market must stop circulating), be auditable (who approved what, when, and which version a rep actually presented), and be gated by market, because approved claims differ between them. The failure mode isn’t losing a file. It’s a rep or an agency confidently using the wrong or expired one. And the honest caveat up front: a DAM doesn’t perform MLR review — it records and enforces the decision your reviewers made.
This page is the pharma and life-sciences asset problem. Because the deciding capability is a review that ends in a recorded sign-off, the tools that fit are the ones we test in our DAM approval workflows ranking; for the guarantee that the approved version is the one people actually retrieve, our version control ranking is the closer fit.
The asset problem in pharmaceuticals & life sciences
Most industries treat a marketing asset as a file: make it, find it, publish it. Pharma can’t. An outward-facing piece — a detail aid, a leave-behind, a congress panel, a banner, an email — carries claims about a medicine, and before it can be used it passes MLR review: medical, legal and regulatory reviewers signing off that the claims are supported and the piece is fit to go out. That review is the expensive part of the process. The asset is just the artefact it produces.
Which relocates the problem entirely. Storage is not the issue; pharma companies have plenty of storage. The issue is that the approval, not the file, is the thing you have to manage — and approvals behave in ways files don’t. They lapse: a piece is approved for a period, and when that period ends it isn’t approved any more even though the file is still perfectly openable. They get withdrawn: a claim changes, a safety update lands, a piece is pulled from market, and every copy of it is supposed to stop being used that day. They are versioned: review approved this version, and the near-identical one with the older figure on page four is not the approved version, it just looks like it. And they are local: what is approved in one market is not automatically approved in another, because the approved claims differ.
Now add who is holding the files. Field reps, medical science liaisons, agencies, distributors and country teams — people outside the marketing team, often offline, often with their own downloaded copies from the last cycle. The realistic failure isn’t that somebody can’t find an asset. It’s that somebody finds one too easily: the expired detail aid still on a tablet, the agency’s folder copy that predates the last revision, the piece approved for a neighbouring market used in this one. Nobody is being reckless. The wrong file was simply the one within reach.
Where a DAM saves money — and risk — here
- The approved version is the only one you can get. Not a folder where the current piece sits next to three lookalikes, but a library where retrieving the asset means retrieving the version that cleared review — superseded ones kept for the record, not for circulation. This is the whole point of real version control: not listing old versions, but controlling which one is at hand.
- Sign-off you can produce, not reconstruct. The approval and its date recorded on the asset, with an audit trail beneath it, so “who approved this, and when?” is a lookup rather than an archaeological dig through a former colleague’s mailbox. The cost avoided is the reconstruction, and the position of not being able to answer at all.
- Expired material stops circulating by default. An expiry date on the asset and a retirement step that fires on it, so a lapsed approval or a withdrawn piece drops out of the retrievable set automatically instead of depending on someone remembering. That’s the asset lifecycle — ingest, approve, distribute, retire — doing the remembering for you.
- One library, gated by market and indication. Granular permissions so a global library shows each market only what’s approved for it, and reps and agencies self-serve the current, approved set from a portal instead of keeping private copies. One source, many correctly fenced views — the governance job our enterprise DAM ranking tests at scale.
How it plays out
An illustrative composite. The scenario below is not one named brand — it is a composite of the patterns we see, built entirely from capabilities we have tested and published. No invented benchmarks.
Picture a mid-size specialty pharma company: two marketed products, a small brand team, an external creative agency, field reps across several countries, and promotional material spread over a shared drive, the agency’s own storage, and whatever each rep downloaded last cycle. Review happens — properly, by real reviewers — and the approved PDF is emailed round when it’s done.
A claim on one product is revised, and the detail aid is re-approved with new wording. The new file goes out by email. But the old one is still on the shared drive beside it, still in the agency’s folder, and still on the tablets of the reps who were travelling that week. Two months on, a piece approved for a neighbouring market gets used locally because it was the version someone had; separately, a congress leave-behind quietly passes its approval date and keeps being handed out, because the date lived in a spreadsheet nobody opens. Then the question arrives — who approved this version, and when? — and the answer takes a fortnight of email forensics, because the reviewer who signed it has left.
In a DAM, the re-approved detail aid supersedes the old one in a single library: the previous version stays on the record but stops being what you get when you go and fetch the piece. The sign-off and its date sit on the asset, so the “who approved this?” question is a lookup. The leave-behind carries an expiry and retires itself on the date. Permissions mean the neighbouring market’s piece never appears in this market’s view of the library, and reps and the agency pull from the portal rather than hoarding copies, so the wrong file isn’t the nearest one. The saving isn’t a percentage we can invent — it is the withdrawn piece that stops going out, the sign-off you can produce on demand, and the fortnight of forensics you don’t spend. To weigh that against tool cost, our business-case guide counts search time, rework and the cost of waiting. Vendors that build for this end of the market tend to wrap the DAM in wider content operations — our researched Aprimo profile is the example on this site.
The capabilities that matter most here
1. An approval workflow that ends in a recorded sign-off
The decisive one. Not a comment thread or a “looks good” email, but a routed review that blocks the asset from use until it’s signed, and then keeps who signed it and when attached to the asset with an audit trail beneath. Note the boundary honestly: the DAM doesn’t make the MLR judgement, it captures and enforces it. The tools that run a real blocking workflow rather than a decorative one are in our approval workflows ranking.
2. Version control where the approved version is the retrievable one
Review approved a specific version. So the library’s job is to make that version the one that comes back — superseded versions retained for the record but out of circulation, not sitting in the same folder looking equally current. Plenty of tools can list old versions; far fewer make the right one unmistakable at the point of retrieval. That gap is what our version control ranking exists to test.
3. Expiry and retirement of lapsed approvals
Approvals run out, and pieces get withdrawn. An asset should therefore carry a date and be retired on it — automatically, not by reminder — so lapsed and withdrawn material leaves the retrievable set the day it should. This is the retire end of the asset lifecycle, and it’s the stage most libraries never actually run.
4. Market-gated permissions and distribution to the field
Approved claims differ by market, so one global library must fence what each market, indication and agency can see — granular permissions, not one big shared drive. And it must push to the people who actually present the material: reps and agencies self-serving the current approved set from a portal rather than working from downloads. For multi-market governance at that scale, see our enterprise DAM ranking.
Buyer’s test: during a trial, approve a piece, then revise and re-approve it — and confirm that a rep-level account searching for it gets only the new version, with the old one on the record but not in reach. Then set an asset to expire yesterday and check it has actually left that account’s results without anyone intervening. Finally, ask the tool who approved version 2 and when, and see whether it answers in one click or sends you back to email. If re-approval, expiry and “who signed this” all hold up unattended, the tool fits pharma; if any of the three needs a human to remember, it doesn’t.
FAQ
Why does a pharma or life-sciences team need a DAM and not just shared folders?
Because here an asset isn't just a file - it's a claim someone signed off on. Every outward-facing, claim-bearing piece goes through MLR review before it can be used, and what matters afterwards is that the approved version is the one in circulation, that you can show who approved it and when, and that it stops being used once the approval lapses or the piece is withdrawn. Shared folders hold files. They can't record a sign-off, can't stop a rep opening last year's copy, and can't retire a piece on a date. The risk in this industry isn't losing an asset. It's using the wrong one.
Does a DAM run MLR review or make us compliant?
No, and treat any vendor who suggests otherwise with suspicion. MLR review is a judgement made by medical, legal and regulatory reviewers, and compliance is a program your regulatory and legal teams own. Plenty of companies run the review itself in a purpose-built promotional-material system rather than a DAM. What a DAM does is hold the outcome of that decision and enforce it: the approved version is the retrievable one, the sign-off and its date sit on the asset, use is logged, and the piece retires when its approval lapses. Those are controls that support your process, not a substitute for it. Confirm any specific obligation with your own regulatory team rather than a marketing page.
How is this different from healthcare, which is also regulated?
The regulated thing is different. In healthcare the sensitive asset is a person - usually a patient - and the job is consent: who agreed to what use, and can you honour a withdrawal. In pharma the sensitive asset is a claim, and the job is approval: did this piece clear review, is this the version that cleared, has the approval expired. One points at the subject of the photograph; the other points at the words and data on the piece. They need different controls, which is why we keep them as separate pages.
How does a DAM stop an expired or withdrawn piece from being used?
By putting an expiry on the asset and retiring it on that date rather than relying on someone to remember. Approvals lapse, and a piece pulled from market has to stop circulating, so each approved asset carries a date and drops out of the retrievable set when the date passes or the piece is withdrawn. Distribution is the other half: if reps and agencies pull from a portal instead of keeping their own copies, the expired piece isn't sitting on a tablet or an agency drive waiting to be used. A DAM can't reach into a file someone already downloaded, but it removes the reason to have one.
Which capability matters most for pharma and life sciences?
The approval workflow with a recorded sign-off, and the audit trail underneath it. Storage and search are table stakes; what decides the tool is whether it can show who approved what, when, and which version a rep actually presented. Close behind is permissions granular enough to gate by market and indication, because approved claims differ between markets and one global library has to ensure a market only sees what's approved for it. Expiry and version control matter too, but they enforce the same thing: the approved decision.
Sources & references
- DAM approval workflows ranking — which tools run a review that actually blocks use until sign-off, and record who signed. The deciding capability for promotional material. July 2026.
- Version control ranking — tested on whether a tool truly restores and controls versions rather than merely listing them, which is what makes the approved version the retrievable one. July 2026.
- Granular permissions ranking and enterprise DAM ranking — gating one library by market and indication, and the multi-brand governance that goes with it. July 2026.
- Audit trail and asset lifecycle — the record of who did what to an asset, and the retire stage that takes lapsed approvals out of circulation.
- Aprimo profile — our researched profile of a content-operations platform aimed at regulated enterprises, from vendor documentation and verified customer reports, not our own testing.
- DAM business-case guide — sizing search time, rework and the cost of waiting against tool cost.
The approval, versioning, expiry and permission capabilities are drawn from our testing and reviews; MLR review is described as general industry practice, and this page states no specific regulatory requirement and quotes no rule text — confirm any obligation with your own regulatory team. The composite pharma company invents no organization and no numbers, per how we source claims. This page is not legal or regulatory advice. See how we test.